Ocular Tuberculosis Therapeutics

Ocular tuberculosis is an extrapulmonary manifestation of infection with Mycobacterium tuberculosis that can involve the uvea, retina, optic nerve, or surrounding ocular tissues. Diagnosis is challenging because ocular findings may resemble noninfectious inflammatory disease, while microbiological confirmation from ocular specimens is often difficult. Therapeutic decisions therefore commonly integrate clinical examination, imaging, systemic evaluation, tuberculosis testing, and assessment of alternative diagnoses. Management generally combines antitubercular therapy with carefully selected anti-inflammatory treatment, with the regimen and duration tailored to disease location, severity, drug susceptibility, and national guidance.

The therapeutic landscape is being reshaped by earlier recognition of ocular presentations, greater use of multimodal imaging, and stronger emphasis on coordinated ophthalmology, infectious-disease, and respiratory care. Clinicians must balance the risk of untreated infection against the risk that corticosteroids or other immunosuppressive therapies could worsen active disease. Drug resistance, hepatotoxicity, drug interactions, adherence challenges, and delayed referral remain important practical constraints. These factors are encouraging more structured diagnostic pathways, treatment monitoring, and individualized decisions rather than reliance on a single test or uniform regimen.

Artificial intelligence may strengthen ocular tuberculosis care by assisting image interpretation, identifying patterns of uveitis or retinal inflammation, prioritizing patients for specialist review, and detecting changes across serial imaging. Its most credible near-term role is decision support rather than autonomous diagnosis. Training data must represent diverse populations, imaging devices, disease stages, and tuberculosis prevalence settings; otherwise, models may reproduce diagnostic bias. Clinical validation, explainability, privacy safeguards, and clear responsibility for final decisions are essential before AI tools influence antimicrobial or immunosuppressive treatment.

North America and Europe generally have strong specialist networks and diagnostic infrastructure, but clinicians must maintain awareness of ocular tuberculosis among migrants, travelers, immunocompromised patients, and people with prior exposure. Latin America combines substantial tuberculosis activity with variable access to subspecialty ophthalmology and diagnostic testing. The Middle East and Africa face wide differences in laboratory capacity, referral pathways, treatment continuity, and access to imaging. Asia-Pacific includes countries with major tuberculosis burdens alongside highly developed ophthalmic systems, creating a broad spectrum of needs. Across all regions, integrated referral, reliable medicine supply, pharmacovigilance, and locally appropriate diagnostic algorithms are central priorities.

ASEAN members face differing tuberculosis burdens, health-system resources, and specialist availability, making shared training and referral protocols valuable. BRICS countries span large and diverse populations, where coordinated research, resistance surveillance, and implementation experience can inform practical care models. The European Union benefits from cross-border scientific and public-health collaboration, although national reimbursement and clinical pathways vary. G7 systems typically possess advanced diagnostics and research capacity but still need equitable access and vigilance in vulnerable populations. GCC countries can leverage centralized health planning and specialist services while addressing mobility and imported-infection considerations. NATO members may benefit from interoperable surveillance, preparedness, and medical referral capabilities without replacing civilian tuberculosis programs.

Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, the United Kingdom, and the United States generally have substantial specialist and laboratory capacity, but practice remains dependent on referral access, diagnostic confidence, and coordination between ophthalmology and tuberculosis services. Brazil, China, India, Mexico, and Russia require approaches attuned to regional variation, tuberculosis control priorities, drug-resistance concerns, and uneven access to subspecialty care. Across all listed countries, effective management benefits from rapid evaluation of suspected disease, review of systemic tuberculosis status, attention to drug interactions and organ toxicity, and follow-up capable of distinguishing infection control from inflammatory relapse.

Industry leaders should support multidisciplinary protocols linking ophthalmologists with infectious-disease, respiratory, laboratory, and pharmacy teams. Priority actions include improving access to ocular imaging and validated laboratory testing; establishing referral criteria for suspected ocular tuberculosis; strengthening adherence support and toxicity monitoring; and maintaining uninterrupted access to quality-assured antitubercular medicines. Organizations should evaluate AI only through clinically representative validation studies, monitor performance across demographic groups, and preserve clinician oversight. Research programs should prioritize prospective cohorts, standardized case definitions, treatment outcomes, resistance-aware strategies, and evidence on when adjunctive anti-inflammatory therapy improves outcomes without increasing infectious risk.

This executive summary uses a clinical and health-system synthesis approach. It integrates established principles of tuberculosis diagnosis and treatment, ophthalmic disease patterns, public-health considerations, antimicrobial stewardship, and developments in diagnostic imaging and clinical AI. Regional, group, and country narratives are framed around documented differences in tuberculosis epidemiology, healthcare capacity, specialist access, and policy coordination rather than commercial measurement. Because ocular tuberculosis is uncommon, heterogeneous, and frequently diagnosed without direct ocular microbiological confirmation, conclusions should be interpreted alongside current national guidelines, local resistance data, and specialist assessment.

Ocular tuberculosis therapeutics require a careful balance of diagnostic uncertainty, infection control, inflammation management, and long-term follow-up. The strongest opportunities are not simply new treatments, but faster recognition, coordinated multidisciplinary decisions, safer monitoring, improved access to specialist services, and responsible use of validated digital tools. Regional and national differences make adaptable pathways essential. Leaders who connect tuberculosis programs with ophthalmic expertise and research can improve diagnostic confidence, protect patients from avoidable treatment harms, and support more consistent outcomes.